Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiteVax Adjuvant-adjuvanted pneumococcal conjugate vaccine
- Development stage
- Preclinical
- Lead developer
- LiteVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LiteVax Adjuvant-adjuvanted pneumococcal conjugate vaccine is an investigational vaccine candidate developed by LiteVax B.V. for the prevention of pneumococcal disease caused by Streptococcus pneumoniae. The vaccine utilizes LiteVax's proprietary adjuvant technology, which consists of specific sucrose fatty acid esters (SFAEs) that act as potent immunostimulants. By combining these SFAEs with pneumococcal conjugate antigens (polysaccharides linked to a carrier protein), the vaccine aims to elicit a superior immune response characterized by high levels of protective antibodies and robust T-cell activation. This approach is intended to provide broader protection across various serotypes and improve vaccine efficacy in populations with weakened immune systems, such as infants and the elderly, while potentially allowing for a reduction in the required dose of conjugate antigens.
- Other names
- LiteVax-adjuvanted PCV
02
Targets
CRM197 (Diphtheria toxin CRM197 mutant)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on LiteVax Adjuvant-adjuvanted pneumococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LiteVax Adjuvant-adjuvanted pneumococcal conjugate vaccine.